Barbara Osband - President & CEO
From the initial founding of Cambridge Biomedical in 1997, Barbara recognized the need in the industry for a company that could serve as more than a provider of testing services to life sciences companies. She has consistently put into place elements that support her vision of becoming a valuable resource to our clients by providing them with unrivaled customer service built on a foundation of solid science and backed by a strong organization with consistent financial performance. Cambridge Biomedical today benefits from her strategic vision and management style as it remains a profitable independent company, able to invest in key areas that allow it to prosper and continue to support its customers. Barbara received degrees from The College of New Rochelle and Sarah Lawrence College.
John Reddington, PhD, DVM - Chief Operating Officer
Dr. Reddington recently served as President and CEO of Sirtex Medical, Inc., the US division of an Australian publicly traded company Sirtex Medical Group Ltd. (ASX: SIR), where he reorganized and revitalized the US division which accounts for approximately 80% of the corporation's Aus$66 million in revenue. During John's last year with Sirtex the divisional sales increased by 29% while expenses were trimmed by 6%, which contributed significantly to the 1,406% increase in net profit (after taxes) that the Company enjoyed.
Prior to joining Sirtex, John was COO and SVP of R&D for the publicly traded company Valentis Inc., where he played a key role in transitioning Valentis' clinical focus from gene therapy to poloxamer-based therapeutics to treat cardiovascular disease. During his tenure John helped secure $30 million in new equity financing, as well as negotiated licensing and supply agreements up to $500 million. In addition, he was responsible for selling off all non-critical assets to facilitate a reverse merger, and spun out the manufacturing division as an independent business unit.
Previously, John founded DiagXotics Inc. and led it to become the world leader in disease diagnosis for the $52-billion global aquaculture market. Earlier in his career, John directed the build-out and operation of an office and cancer cell therapy laboratory for Greenwich Biotherapeutics Inc. a joint venture between Biotherapeutics Inc., Yale University and Greenwich Hospital. Dr Reddington received his B.A. from Rice University, his M.A. from the University of Texas, Arlington and his DVM and PhD from Washington State University.